Bonifácio, Lívia Pimenta 
; Ramacciotti, Eduardo ; Agati, Leandro Barile ; Vilar, Fernando Crivelenti; Silva, Anna Christina Tojal da; Louzada Junior, Paulo; Fonseca, Benedito Antonio Lopes da; Souza, Hayala Cristina Cavenague de; Oliveira, Caroline Candida Carvalho de; Aguiar, Valeria Cristina Resende; Kallas, Esper Georges ; Rodrigues, Fernando Bellíssimo
Source: Revista da sociedade brasileira de medicina tropical. Unidades: FMRP, FM
Subjects: COVID-19, PACIENTES INTERNADOS, PANDEMIAS, BRASIL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BONIFÁCIO, Lívia Pimenta et al. Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors). Revista da sociedade brasileira de medicina tropical, v. 56, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/54695. Acesso em: 05 nov. 2024.APA
Bonifácio, L. P., Ramacciotti, E., Agati, L. B., Vilar, F. C., Silva, A. C. T. da, Louzada Junior, P., et al. (2023). Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors). Revista da sociedade brasileira de medicina tropical, 56. doi:10.1590/0037-8682-0565-2022NLM
Bonifácio LP, Ramacciotti E, Agati LB, Vilar FC, Silva ACT da, Louzada Junior P, Fonseca BAL da, Souza HCC de, Oliveira CCC de, Aguiar VCR, Kallas EG, Rodrigues FB. Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors) [Internet]. Revista da sociedade brasileira de medicina tropical. 2023 ; 56[citado 2024 nov. 05 ] Available from: https://observatorio.fm.usp.br/handle/OPI/54695Vancouver
Bonifácio LP, Ramacciotti E, Agati LB, Vilar FC, Silva ACT da, Louzada Junior P, Fonseca BAL da, Souza HCC de, Oliveira CCC de, Aguiar VCR, Kallas EG, Rodrigues FB. Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors) [Internet]. Revista da sociedade brasileira de medicina tropical. 2023 ; 56[citado 2024 nov. 05 ] Available from: https://observatorio.fm.usp.br/handle/OPI/54695
